LogicBio Therapeutics is a genetic medicine company, founded to deliver the benefits of genome editing to the fight against early onset childhood diseases. Launched in 2016 by pioneers in gene therapy from Stanford University and funded by leading life science investors, LogicBio is developing a pipeline of safe and durable treatments for pediatric indications. Our core technology, GeneRideā„¢, enables the site-specific integration of a therapeutic transgene, in a nuclease-free and promotor-less approach by relying on the native process of homologous recombination to drive lifelong expression. With a world-class global team headquartered in Cambridge, Mass., LogicBio is committed to developing medicines that will transform the lives of pediatric patients and their families.

Contact LogicBio Therapeutics
contact@logicbio.com
Paul Goldsmith, Ten Bridge Communications, Paul@Tenbridgecommunications.com, 617-697-3479
Visit Website